Diligence memo · auto-generated · as of July 2, 2026
Acenxion Biosytems, Inc.
Acenxion Biosytems, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Acenxion Biosytems, Inc. operates in Biotechnology, based in LAWRENCE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Acenxion Biosytems, Inc. has raised $1.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2024-07-19.
Most recent recorded round closed around 2024-07-19.
Valuation (modeled)modeled
Provath models Acenxion Biosytems, Inc. at approximately $5.0M (range $770K–$13M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Last raise 23 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).
Modeled value ranks above 10% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.